Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
J Crohns Colitis. 2020 Nov 7;14(11):1600-1610. doi: 10.1093/ecco-jcc/jjaa094.
Dysbiosis of the gut microbiota is a well-known correlate of the pathogenesis of inflammatory bowel disease [IBD]. However, few studies have examined the microbiome in very early-onset [VEO] IBD, which is defined as onset of IBD before 6 years of age. Here we focus on the viral portion of the microbiome-the virome-to assess possible viral associations with disease processes, reasoning that any viruses potentially associated with IBD might grow more robustly in younger subjects, and so be more detectable.
Virus-like particles [VLPs] were purified from stool samples collected from patients with VEO-IBD [n = 54] and healthy controls [n = 23], and characterized by DNA and RNA sequencing and VLP particle counts.
The total number of VLPs was not significantly different between VEO-IBD and healthy controls. For bacterial viruses, the VEO-IBD subjects were found to have a higher ratio of Caudovirales vs to Microviridae compared to healthy controls. An increase in Caudovirales was also associated with immunosuppressive therapy. For viruses infecting human cells, Anelloviridae showed higher prevalence in VEO-IBD compared to healthy controls. Within the VEO-IBD group, higher levels of Anelloviridae DNA were also positively associated with immunosuppressive treatment. To search for new viruses, short sequences enriched in VEO-IBD samples were identified, and some could be validated in an independent cohort, although none was clearly viral; this provides sequence tags to interrogate in future studies.
These data thus document perturbations to normal viral populations associated with VEO-IBD, and provide a biomarker-Anelloviridae DNA levels-potentially useful for reporting the effectiveness of immunosuppression.
肠道微生物群落失调是炎症性肠病 [IBD] 发病机制的已知相关因素。然而,很少有研究检查过非常早发性 [VEO] IBD 的微生物组,VEO-IBD 的定义为发病年龄在 6 岁之前。在这里,我们专注于微生物组的病毒部分 - 病毒组 - 以评估与疾病过程相关的潜在病毒关联,推理是任何与 IBD 相关的潜在病毒在年轻受试者中可能更健壮地生长,因此更易检测到。
从患有 VEO-IBD [n = 54] 和健康对照 [n = 23] 的患者粪便样本中纯化病毒样颗粒 [VLPs],并通过 DNA 和 RNA 测序以及 VLP 颗粒计数进行表征。
VEO-IBD 和健康对照组之间的 VLPs 总数没有显着差异。对于细菌病毒,与健康对照组相比,VEO-IBD 受试者的 Caudovirales 与 Microviridae 的比例更高。Caudovirales 的增加也与免疫抑制治疗有关。对于感染人类细胞的病毒,与健康对照组相比,VEO-IBD 中 Anelloviridae 的患病率更高。在 VEO-IBD 组中,Anelloviridae DNA 水平也与免疫抑制治疗呈正相关。为了寻找新的病毒,鉴定了在 VEO-IBD 样本中富集的短序列,并且一些可以在独立队列中得到验证,尽管没有明确的病毒;这提供了可以在未来研究中进行查询的序列标签。
这些数据记录了与 VEO-IBD 相关的正常病毒群的扰动,并提供了一种生物标志物 - Anelloviridae DNA 水平 - 可能有助于报告免疫抑制的有效性。